The characteristics of NO donors, NOC5 [3-(2-hydroxy-1-(1-methylethyl-2-nitrosohydrazino)-1-propanamine), NOC12 [N-ethyl-2-(1-ethyl-2-hydroxy-2-nitrosohydrazino)-ethanamine] and SNAP [S-nitroso-N-acetyl-DL-penicillamine] as absorption enhancers for poorly absorbable drugs were examined in rats using an in situ closed loop method. They were compared with a group of conventional absorption enhancers including sodium glycocholate (NaGC), sodium caprate (NaCap), sodium salicylate (NaSal) and n-dodecyl-b-D-maltopyranoside (LM). 5(6)-carboxy‰uorescein (CF) was used as a model drug to investigate eŠectiveness, site-dependency, and concentration-dependency of the tested enhancers. Overall, the NO donors can improve the intestinal absorption of CF at low concentration (5 mM), whereas higher concentration was required for the conventional absorption enhancers to elicit the absorption enhancing eŠect. In the small intestine, SNAP was the most eŠective absorption enhancers, although its concentration (5 mM) was lower than the conventional absorption enhancers (20 mM). On the other hand, LM and NaCap as well as the three NO donors were eŠective to improve the colonic absorption of CF. In the regional diŠerence in the absorption enhancing eŠects, the NO donors showed signiˆcant eŠects in all intestinal regions, whereas we observed a regional diŠerence in the absorption enhancing eŠect of the other conventional absorption enhancers. In the conventional enhancers, the absorption enhancing eŠects were generally greater in the large intestine than those in the small intestine. LM and NaCap were ineŠective in the jejunum, although they were eŠective for improving the absorption of CF in the colon. NaSal was ineŠective in both the jejunum and the colon. The absorption enhancement produced by NO donors was greatly aŠected by increasing the enhancer concentration from 3 to 5 mM, but only a slight increase was obtained when the concentration was raised to 10 mM. Similar results were obtained for the other enhancers over the range of 10 to 20 mM, but the absorption enhancing eŠects of these enhancers were almost saturated above these concentrations. These results suggest that NO donors possess excellent eŠectiveness as absorption enhancers for poorly absorbable drugs compared with the conventional enhancers. They can enhance intestinal absorption of CF from all intestinal regions and they are eŠective at very low concentrations.
Introduction
The absorption of polar drugs is frequently limited by their poor intestinal permeability. The use of absorption enhancers has been shown to improve the absorption characteristics of these drugs. Various kinds of absorption enhancers have been investigated regarding their eŠectiveness, toxicity and mechanism of action. [1] [2] [3] [4] [5] Most of the enhancers presently available improve the absorption of polar drugs and macromolecules from the rectum or large intestine, and there have been only few reports of those improving absorption from the small intestine. 6, 7) NO, a major secretory product of mammalian cells, has been identiˆed as an important regulator and W or eŠector of many phenomena in cardiovascular, nervous and immune systems. 8) Moreover, NO also plays a versatile role in the physiological and pathophysiological functions of the gastrointestinal tract. 9) Regarding the absorption enhancing action of NO donors, Salzman et al. 10) reported that NO donors had the ability to increase the permeability of water-soluble compounds across Caco-2 cell monolayers. Utoguchi et al. demonstrated that the rectal absorption of insulin was remarkably enhanced in the presence of NO donors. 11) More recently, we demonstrated that NO donors improved the intestinal absorption of insulin and [Asu 1, 7 ]-eel calcitonin by in vitro and in situ absorption studies. 12) However, few studies have been carried out to compare the absorption enhancing eŠects of NO donors with those of conventional absorption enhancers in the diŠerent intestinal regions using intact intestinal membranes.
In this study, CF was chosen as a model of poorly absorbable drugs and the characteristics (eŠectiveness, site-dependency and concentration-dependency) of NO donors for enhancing the intestinal absorption of CF were examined by an in situ closed loop method. We also compared their absorption enhancing eŠects with those of various types of conventional enhancers in diŠerent intestinal regions.
Materials and Methods
Materials: CF was obtained from Eastman Kodak Company (Rochester, NY, USA). NOC5 [3-(2- 
and SNAP [S-nitroso-N-acetyl-DLpenicillamine] were purchased from Dojindo Laboratories (Kumamoto, Japan). LM and NaGC were obtained from Sigma Chemical Co. (St. Louis, MO, USA). NaSal and NaCap were bought from Nacalai Tesque, inc. (Kyoto, Japan). All other reagents used were of analytical grade.
Preparation of drug solution: For the absorption studies, the drug was dissolved in a phosphate buŠered saline solution (PBS) adjusted to pH 7.4 to aˆnal concentration of 0.125 mg W mL. NO donors were added in concentrations of 3, 5 and 10 mM, while the other enhancers were added in concentrations of 10, 20 and 30 mM.
Absorption experiments: Absorption experiments were performed by an in situ closed loop method. [13] [14] [15] Studies in this article have been carried out in accordance with the guidelines of the animal ethics committee at Kyoto Pharmaceutical University. Male Wistar albino rats (250-280 g) were anaesthetized with sodium pentobarbital (32 mg W kg body weight i.p.). Animals were fasted for about 16 hr before the experiment. The intestine was exposed through a midline abdominal incision and ‰ushed by passing phosphate buŠered saline (PBS, pH 7.4). A closed loop was prepared of each of jejunum, ileum and colon. The distal part of the loop was cannulated with polyethylene tubing then closed by clipping with a forceps. Drug solution (2 mL), kept at 379 C, was introduced into the loop through a cannulated opening in the proximal part of the loop, which was then closed with forceps. The jugular vein was exposed and blood samples (¿0.3 mL) were collected into heparinized syringes at predetermined time intervals up to 240 min. Samples were immediately centrifuged at 10000 rpm for 5 min to obtain the plasma fraction (100 mL), which was then kept in ice until determination. The plasma samples of CF were determined by a modiˆed method of Masuda et al.. 16) An equal volume of 10z (v W v) Triton X-100 solution was added to each plasma sample, samples were then determined spectro‰uorometrically. The intravenous administration of an equivalent dose was carried out separately via the femoral vein. The peak concentration (Cmax) and the time to reach the peak concentration (Tmax) were determined directly from the plasma concentration-time curves. The area under the curve (AUC) was calculated by the trapezoidal method from zero to theˆnal sampling time (240 min). The extent of bioavailability was calculated as follows:
Determination (assay) of drug: CF was determined spectro‰uorometrically using microplate reader ‰uores-cence spectrophotometer (Spectra‰uor Plus, TECAN, Austria GmbH) at an excitation wavelength of 485 nm and an emission wavelength of 535 nm.
Statistical analyses: Results were expressed as the mean±S.E. and statistical signiˆcance was assessed by the Student's t test and Dunnett's test for multiple comparison.
Results
EŠect of NO donors and other conventional absorption enhancers on the intestinal absorption of CF: We examined the eŠects of NO donors and other conventional absorption enhancers on the absorption of CF from the various intestinal regions by an in situ closed loop method. Figure 1 shows the plasma concentration-time proles of CF in the presence or absence of various absorp- tion enhancers following administration to the jejunal loops of rats. As shown in thisˆgure, all three NO donors increased the jejunal absorption of CF and we observed a signiˆcant increase in the plasma concentration of CF in the presence of these NO donors ( Fig. 1(A) ). However, the absorption of CF from the jejunum was not enhanced by the addition of these conventional absorption enhancers, except for NaGC ( Fig. 1(B) ). Table 1 summarizes the pharmacokinetic parameters of CF with or without various absorption enhancers. As indicated in this table, all the NO donors, especially SNAP increased the peak plasma concentration (Cmax), AUC and Fz of CF as compared with the control, although the time to reach the peak plasma concentration (Tmax) of CF with SNAP was slightly delayed as compared with the control. On the other hand, of all the conventional absorption enhancers, only NaGC signiˆcantly increased the Cmax, AUC and Fz of CF from the jejunum, but other enhancers did not. Therefore, theseˆndings indicated that the three NO donors improved the jejunal absorption of CF in rats, although their concentrations (5 mM) were much less than those of the conventional absorption enhancers (20 mM). Figure 2 indicates the plasma concentration-time proˆles of CF in the presence or absence of various absorption enhancers following administration to ileal loops of rats. The NO donors signiˆcantly increased the ileal absorption of CF as shown in Fig. 2(A) . Obtained pharmacokinetic parameters also clearly showed that Table 2) . Similarly, the absorption of CF from the ileum was enhanced by the addition of NaGC, while we observed a moderate increase in the absorption of CF in the presence of other conventional absorption enhancers ( Fig. 2(B) and Table 2 ). However, the absorption enhancing eŠects of these enhancers except for NaGC were less than those of the NO donors. Figure 3 demonstrates the plasma concentration-time proˆles of CF in the presence or absence of various absorption enhancers following administration to colonic loops of rats. Pharmacokinetic parameters are summarized in Table 3 . The absorption of CF from the colon without any absorption enhancer was very limited and we observed very low plasma concentrations following the colonic administration of CF in the control studies. However, the colonic absorption of CF was markedly enhanced by the addition of these NO donors (5 mM) and the Cmax, AUC value and Fz of CF remarkably increased in the presence of these NO donors (Fig. 3(A) and Table 3 ). On the other hand, the conventional absorption enhancers (20 mM), especially LM was very eŠective to enhance the colonic absorption of CF, although NaSal did not increase the colonic absorption of CF at this concentration (Fig. 3(B) and Table 3 ). Of all these conventional enhancers, LM had the best absorption enhancing eŠect in the colonic region.
EŠect of various concentrations of NO donors and other conventional absorption enhancers on the intestinal absorption of CF: Based on the regionally diŠer-ent eŠects of various absorption enhancers, colon is the best administration site to elicit the absorption enhancing eŠect of these absorption enhancers. Therefore, we selected colonic region as a suitable site for further evaluation of the absorption enhancement eŠect of these enhancers. The eŠect of various concentrations of NO donors and other conventional absorption enhancers on the colonic absorption of CF was examined by the in situ closed loop method at 3, 5 and 10 mM for NO donors and at 10-30 mM for the conventional absorption enhancers, and the obtained pharmacokinetic parameters of CF are summarized in Table 4 . As the concentration of NO donors increased, their e‹cacy (AUC and Cmax) signiˆcantly increased. Particularly, the enhancing eŠect was greatly increased when the concentration was changed from 3 to 5 mM, but the e‹cacy was almost saturated at above these concentrations. Overall, the NO donors were very eŠective for improving the intestinal absorption of CF at low concentrations. In the case of conventional absorption enhancers, the AUC value and Fz of CF gradually increased, as the concentration of NaGC, NaCap and LM increased. Therefore, theseˆndings indicated that the absorption enhancing eŠect of these enhancers also increased with increasing their concentrations from 10 to 20 mM. The Cmax of CF also increased by increasing the concentration of these enhancers, whereas T max was not aŠected. When the concentration of these enhancers increased from 20 to 30 mM, only a slight increase in the pharmacokinetic parameters was observed. In this study, NaSal was not included, because it did not show any signiˆcant enhancing eŠect.
Discussion
We used three kinds of NO donors in this study. NOC5 and NOC12 belong to the NONOates (1-substituted diazen-1-ium-1,2-diolates), which release NO spontaneously when placed in buŠer. [17] [18] [19] SNAP was chosen from the S-nitrosothiols group, agents of this group release NO through enzymatic or non-enzymatic cleavage of the S-NO bond. 20, 21) These NO donors diŠer in the NO release rate and the half-life of the released NO. In this study, we observed that the extent of absorption enhancing eŠect of each NO donor was diŠerent and in general, the rank order of the eŠective-ness of these NO donors was SNAPÀNOC12ÀNOC5. This diŠerence may be due to the amount and rate of NO released from these NO donors, although we do not have the data about its amount and rate at present. However, it was known that the half life of NOC5 and NOC12 in PBS solution (pH 7.4) at 379 C was 7 and 13 min, respectively. 12) Therefore, such diŠerent half-life may be one of the important factors aŠecting the extent of absorption enhancing eŠect of these NO donors.
In this study, the diŠerent types of conventional absorption enhancers were employed for improving the intestinal absorption of CF and compared with NO donors in their eŠectiveness. In general, the absorption enhancing eŠects of NO donors were generally more eŠective than those of the conventional absorption enhancers, although the concentration of NO donors (5 mM) was much less than that of the conventional enhancers (20 mM). The rank order of the eŠectiveness of absorption enhancers in the small intestine (jejunum and ileum) is as follows; SNAPÀNOC12＝NaGCÀ NOC5ÀNaSal＝NaCap＝LM. On the other hand, the rank order in the large intestine (colon) is as follows; SNAPÀNOC12 ＝ LM ＝ NOC5ÀNaCapÀNaGCÀ NaSal. Theseˆndings suggest that these NO donors, especially SNAP is very eŠective for improving the intestinal absorption of poorly absorbable drugs at low concentration.
Regional diŠerences were observed in the enhancing eŠect of all tested enhancers on the intestinal absorption of CF by in situ absorption studies. However, that regional diŠerence was not very pronounced in case of NO donors compared with the other group. It was previously found that the absorption-enhancing eŠects of NaCap, LM and EDTA for ebiratide absorption were greater in the colon than those in the jejunum. 22) On the other hand, Numata and co-workers 23) reported no regional diŠerence in the absorption-enhancing eŠect of NOC7 on the absorption of FD-4 by the in situ loop method. They found that FD-4 absorption was signiˆcantly increased after coadministration with NOC7 in all the regions of intestine (jejunum, colon and rectum). More recently, we found that NO donors improved the intestinal absorption of insulin and [Asu 1, 7 ]-eel calcitonin from all the intestinal regions. 12) Therefore, the presentˆndings were consistent with the previous results of absorption enhancers applied in the diŠerent intestinal regions and indicate that the absorption enhancing eŠect of NO donors is still signiˆcant in the small intestinal regions as compared with the conventional absorption enhancers. Therefore, NO donors are eŠective absorption enhancers not only in the large intestinal region but also in the small intestinal region, where the conventional absorption enhancers were generally ineŠective. This study showed that the absorption-enhancing eŠects of the tested NO donors were dose-dependent over the range of 3 to 5 mM ( Table 4) . Utoguchi et al. 11) reported that the absorption-enhancing eŠect of SNAP for rectal insulin absorption was dose dependent over the range of 0.25 to 4.0 mg in rats. Salzman et al. 10) also reported that incubation with sodium nitroprusside (SNP) resulted in a concentration-dependent increase in the transepithelial transport of ‰uorescein sulfonic acid in Caco-2 cells. Thus, our present results concur with these previous studies.
The mechanism by which these NO donors increase the intestinal absorption of CF was examined in our previous studies. We found that NOC12 signiˆcantly decreased the transepithelial electrical resistance (TEER) value of the colonic membrane and this decreased TEER value by NOC12 recovered to the control level in the presence of carboxy-PTIO, a typical NO scavenger. 24) Moreover, CF is usually used as a model drug that can be transported via a paracellular pathway and we observed an increase in the intestinal absorption of CF by various NO donors. Therefore, theseˆndings suggest that the absorption enhancing eŠect of NO donors would be ascribed to the dilation of tight junction in the epithelium via a paracellular pathway.
To apply NO donors into clinical use, these adjuvants should not be toxic to the intestinal mucosal membrane. We previously showed that the absorption enhancing eŠect of NOC12 was reversible and less toxic to the colonic mucosal membrane than the conventional absorption enhancers, which was assessed by the pretreatment studies with NOC12 and LDH release studies. 23) In addition, it was reported that little cytotoxicity of SNAP, assessed in terms of the rate of LDH release from Caco-2 cells, was detected for 2 hr incubation.
11) Numata et al. also demonstrated the similar results with the low toxicity of NO donors as assessed by the release of protein and LDH from the intestinal mucosa. 24) Furthermore, it was indicated that SNAP had a very low potential for cytotoxicity, as evaluated by the cell detachment assay, release of LDH from culture cells and morphological observations of nasal tissue of rabbit. 25) From theseˆndings, therefore, NO donors would be less toxic to the intestinal membranes than the conventional absorption enhancers.
In conclusion, our presentˆndings indicate that the intestinal absorption of CF was signiˆcantly enhanced by NO donors in both the small and large intestine. Their eŠect was not so site-dependent and not so regional speciˆc, although other conventional enhancers showed the regional diŠerence. In addition, the minimal concentration of NO donors required for eliciting the absorption enhancing eŠect is very low as compared with the conventional enhancers. Therefore, the NO donors would be excellent absorption enhancers for improving the intestinal absorption of poorly absorbable drugs.
